Symposium to Include Podium Presentations, New Data and Panel Discussion Featuring Distinguished U.S. Urologists
HASBROUCK HEIGHTS, N.J., April 24, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2012 Annual Meeting of the American Urological Association in Atlanta, GA 3:00 p.m. May 20. The Symposium will be held in the Georgia World Congress Center.
The symposium, "Clinical studies of NX-1207: Phase 3 Injectable for BPH," will be chaired by Ronald Tutrone Jr, MD, FACS of Towson, MD, who has participated in three of the prospective NX-1207 clinical trials as well as follow-up studies. Dr. Tutrone will present an overview of NX-1207 and the NX-1207 clinical trials to date, including the two Phase 3 clinical trials currently in progress.
Barton H. Wachs, MD, FACS, of Long Beach, CA, will present data from the new studies of the long-term efficacy of NX-1207 treatment. Mohamed Bidair, MD, FACS(C) of San Diego, CA, and Nicholas Franco, MD, FACS of Naples, FL will participate in the panel discussion in the symposium, along with Dr. Tutrone and Dr. Wachs.
All four symposium panelists are distinguished Board-certified urologists with extensive experience as clinical investigators in FDA-regulated clinical trials, including the NX-1207 clinical trials.
NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and Phase 2 for localized prostate cancer. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7½ years.
NX-1207 is in Phase 3 the last stage before filing with the FDA for approval. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to www.clinicaltrials.gov or contact Nymox at email@example.com.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation